Skip to content

A Comparative study on the effect of Vaman Karma with Raktachandanadi lepa and kaishor Guggulu in the management of Yauvan Pidika (Acne Vulgaris)

A Comparative study on the efficacy of Vaman Karma with Raktachandanadi lepa and kaishor Guggulu in the management of Yauvan Pidika w.s.r. to Acne Vulgaris

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/02/007828
Enrollment
30
Registered
2017-02-10
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Yauvan Pidika ( Acne vulgaris)

Interventions

Intervention1: Efficacy of vaman karma with raktachandanadi lepa and kaishor guggulu in management of yauvan pidika w.s.r. to Acne vulgaris: GROUP-A 15 patients will be treated with Vaman Karma follow

Sponsors

Govt Akhandanand Ayurved College and Hospital Bhadra Ahmedabad
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Vaman Yogya as per Ayurvedic text 2 The person between the age of 16-30 years 3 Having classical signs of Yauvan Pidika like Paka ,Srava, Kandu, Vedana, Daha, Vaivarnyata and also signs of Acne Vulgaris like Comedone, Papules, Pustules, Nodules, Cysts, Abscess

Exclusion criteria

Exclusion criteria: Vaman Ayogya as per Ayurvedic texts Diseases like Hypertension, Asthma, Heart disease & other systemic disorders which may lead the patient to fatal condition during Vaman karma Any other skin disease on face

Design outcomes

Primary

MeasureTime frame
improvement in symptoms of yauvan pidikaTimepoint: after completion of treatment

Secondary

MeasureTime frame
improvement in symptoms of yauvan pidikaTimepoint: After completion of treatment

Countries

India

Contacts

Public ContactDr Sweety Ruparel

Govt.Akhandanand ayurvedic college

sweetyruparel@gmail.com9429202048

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026